119 related articles for article (PubMed ID: 21124844)
21. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
[TBL] [Abstract][Full Text] [Related]
23. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
[TBL] [Abstract][Full Text] [Related]
24. Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.
Castillo-Mancilla JR; Brown TT; Erlandson KM; Palella FJ; Gardner EM; Macatangay BJ; Breen EC; Jacobson LP; Anderson PL; Wada NI
Clin Infect Dis; 2016 Dec; 63(12):1661-1667. PubMed ID: 27660234
[TBL] [Abstract][Full Text] [Related]
25. Trends in detectable viral load by calendar year in the Australian HIV observational database.
Law MG; Woolley I; Templeton DJ; Roth N; Chuah J; Mulhall B; Canavan P; McManus H; Cooper DA; Petoumenos K;
J Int AIDS Soc; 2011 Feb; 14():10. PubMed ID: 21345234
[TBL] [Abstract][Full Text] [Related]
26. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?
Braithwaite RS; Nucifora KA; Yiannoutsos CT; Musick B; Kimaiyo S; Diero L; Bacon MC; Wools-Kaloustian K
J Int AIDS Soc; 2011 Jul; 14():38. PubMed ID: 21801434
[TBL] [Abstract][Full Text] [Related]
27. An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy.
Alagaratnam J; Peters H; Francis K; Kay N; Gilleece Y; Finnerty FP; Grimes RE; Parry S; Portman M; Wait BC; Shah R; Roedling S; Hawkins DA; Chitty S; Sarner L; Marcus R; Hartley A; Nori AV; Rosenvinge M; Taylor GP;
AIDS Res Ther; 2020 Jul; 17(1):41. PubMed ID: 32660502
[TBL] [Abstract][Full Text] [Related]
28. Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study.
Kayigamba FR; Franke MF; Bakker MI; Rodriguez CA; Bagiruwigize E; Wit FW; Rich ML; Schim van der Loeff MF
PLoS One; 2016; 11(7):e0159446. PubMed ID: 27438000
[TBL] [Abstract][Full Text] [Related]
29. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
Armenia D; Di Carlo D; Cozzi-Lepri A; Calcagno A; Borghi V; Gori C; Bertoli A; Gennari W; Bellagamba R; Castagna A; Latini A; Pinnetti C; Cicalini S; Saracino A; Lapadula G; Rusconi S; Castelli F; Di Giambenedetto S; Andreoni M; Di Perri G; Antinori A; Mussini C; Ceccherini-Silberstein F; Monforte AD; Perno CF; Santoro MM;
Antivir Ther; 2019; 24(5):321-331. PubMed ID: 30977466
[TBL] [Abstract][Full Text] [Related]
30. Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?
Ateba Ndongo F; Warszawski J; Texier G; Penda I; Tetang Ndiang S; Ndongo JA; Guemkam G; Sofeu CL; Kfutwah A; Faye A; Msellati P; Tejiokem MC;
BMC Pediatr; 2015 Sep; 15():132. PubMed ID: 26391474
[TBL] [Abstract][Full Text] [Related]
31. Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?
Gatey C; Brun A; Hamet G; Diamantis S; Sellier P; Bouchaud O; Garrait V; Rozenbaum W; Molina JM; Abgrall S;
HIV Med; 2019 Feb; 20(2):175-181. PubMed ID: 30506853
[TBL] [Abstract][Full Text] [Related]
32. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with 10 years of continuous viral load suppression on HAART.
Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
[TBL] [Abstract][Full Text] [Related]
34. Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study.
Dragovic G; Smith CJ; Jevtovic D; Dimitrijevic B; Kusic J; Youle M; Johnson MA
BMC Infect Dis; 2016 Mar; 16():106. PubMed ID: 26939611
[TBL] [Abstract][Full Text] [Related]
35. Point-of-care viral load monitoring: outcomes from a decentralized HIV programme in Malawi.
Nicholas S; Poulet E; Wolters L; Wapling J; Rakesh A; Amoros I; Szumilin E; Gueguen M; Schramm B
J Int AIDS Soc; 2019 Aug; 22(8):e25387. PubMed ID: 31441242
[TBL] [Abstract][Full Text] [Related]
36. Timing of intermittent seminal HIV-1 RNA shedding in patients with undetectable plasma viral load under combination antiretroviral therapy.
Ferraretto X; Estellat C; Damond F; Longuet P; Epelboin S; Demailly P; Yazbeck C; Llabador MA; Pasquet B; Yazdanpanah Y; Matheron S; Patrat C
PLoS One; 2014; 9(3):e88922. PubMed ID: 24594873
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
38. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.
Bisson GP; Gross R; Bellamy S; Chittams J; Hislop M; Regensberg L; Frank I; Maartens G; Nachega JB
PLoS Med; 2008 May; 5(5):e109. PubMed ID: 18494555
[TBL] [Abstract][Full Text] [Related]
39. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
40. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
